FDI into Irish pharma has almost exclusively targeted in biologics production over the last few years, largely due to Ireland’s skilled workforce of bioprocessing technicians. NIBRT director Dominic Carolan discusses how the institute supports the Irish biopharma industry through training and recruitment solutions, while pursuing research that may help to reduce the cost of manufacturing biologics.
From your perspective, how have you seen the industry change since you stepped down as chairman of PharmaChemical (now BioPharmaChem) Ireland in 2010?
The industry has experienced a resurgence of FDI in investment, particularly in the area of large molecule or biologics manufacturing
